Skip to main content

Lexeo Therapeutics, Inc.

LXEO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001907108

In the last 90 days, Lexeo Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 141 institutions reported holding it in 13F filings for Q2 2026, worth $410.9M in total; no superinvestor holds it.

Superinvestors holding LXEO, Q2 2026

See all superinvestors

No superinvestor reported holding LXEO in Q2 2026.

Moves by quarter

Superinvestors that opened, added to, trimmed or sold out of LXEO each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.

  1. Q4 2025

    0 superinvestors holding at quarter end

    Sold out
    D1 Capital Partners
  2. Q1 2025

    1 superinvestor holding at quarter end

    Reduced
    D1 Capital Partners (−55.6%)
  3. Q4 2024

    1 superinvestor holding at quarter end

    Reduced
    D1 Capital Partners (−12.1%)
  4. Q4 2023

    1 superinvestor holding at quarter end

    New
    D1 Capital Partners